Immatics N.V. Ordinary Shares
IMTXImmatics N.V. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company specializes in T-cell receptor (TCR) therapies, aiming to harness the immune system to target and destroy tumor cells. Based in Germany, Immatics advances personalized medicine approaches through its proprietary technological platform to identify and develop targeted treatments for various cancers.
Company News
Immatics N.V. plans to sell 12.5 million ordinary shares at $10.00 per share, expecting to raise $125 million in a public offering managed by Jefferies, Leerink Partners, and Cantor.
U.S. stocks closed higher on Tuesday as investors digested the key inflation data that heightened worries regarding inflation.
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock...
Investors liked what they heard in Immatics' interim results for experimental immunotherapy IMA203.
